Chief, Division of Breast Oncology @DanaFarber Tennis fan Mother of two teenage girls
Boston. MA
Joined December 2015
- Tweets8.7K
- Following638
- Followers13.1K
- Likes28.3K
Sara Tolaney retweeted
Dr. Frederick Howard, MD (@fredhow), Assistant Professor in the Department of Medicine, University of Chicago, gave the Susan E. Donelan #InflammatoryBreastCancer Lecture in our Breast Oncology Seminar Series. He gave a talk focusing on artificial intelligence insights into the diagnosis, biology, and precision treatment of #IBC.
Sara Tolaney retweeted
A PD-L1 result now decides whether a patient with metastatic TNBC gets pembrolizumab-based therapy or an ADC first, and both paths carry toxicities that need different monitoring.
Explore more with @stolaney1 and @Neil_Iyengar in this free CME activity: bit.ly/4yXHb4d
Sara Tolaney retweeted
👉 How can collaboration help reduce unnecessary complexity in clinical research? Join a discussion on how cross-stakeholder collaboration can help create a more sustainable, effective research environment
🔗Register now: ow.ly/eCgF50ZZn0c
#ESMOWebinar
@FAndreMD @JlgraciaMD @stolaney1 @TeresaSAmaral @ASCO
Sara Tolaney retweeted
❗️@DrEricWiner & I had the joy of mentoring @minasedrakmd as #VailWorkshop #bcsm faculty in 2018. We both adored him as a creative problem solver & a generous colleague who cares deeply for patients. He is EXACTLY the person you want nominating @ASCO leaders. Vote! 🗳️ #OncTwitter
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Nominating Committee. Visit asco.org/election to learn more about the candidates and place your vote!
Sara Tolaney retweeted
Congratulations to @DanaFarber’s @judygarber5, recipient of the prestigious 2026 Basser Global Prize in recognition of her pioneering and transformative contributions to the treatment and understanding of BRCA-related cancers.
➡️bit.ly/47GHWn0
Sara Tolaney retweeted
FourLight-1 presented by @antgiorda at #ESMO26
Atirmociclib + fulvestrant improved median PFS vs investigator’s choice after CDK4/6i progression in HR+/HER2− metastatic breast cancer (9.4 vs 6.6 months; HR 0.60; p=0.0007)
@DFCI_BreastOnc @OncoAlert
Sara Tolaney retweeted
A new signal for targeting CDK4 after CDK4/6 progression. 🧬
In phase 2 #FOURLIGHT1, atirmociclib + fulvestrant reduced the risk of progression or death by 40% versus investigator’s choice in HR+/HER2− advanced breast cancer.
📊 Median PFS: 9.4 vs 6.6 months
The comparator was fulvestrant or everolimus + exemestane. These findings support continued development of selective CDK4 inhibition, with OS still immature and atirmociclib investigational.
🔎 Read more:
oncologynexus.com/conference…
#ESMO26 #BreastCancer #bcsm @antgiorda @hoperugo @cityofhope @DFCI_BreastOnc @myESMO
Sara Tolaney retweeted
🧠 DESTINY-Breast09 | ESMO 2026
T-DXd + pertuzumab vs THP — first-line HER2+ metastatic breast cancer.
Exploratory CNS analysis (n=61):
• CNS response: 51.6% vs 26.7%
• Complete CNS response: 35.5% vs 23.3%
• CNS-PFS: NR vs 9.7 months (HR 0.26)
• Overall PFS (CNS subgroup): 36.5 vs 11.1 months
• Full trial PFS: 40.7 vs 26.9 months
💡 Take-home: Nearly double the brain response and markedly longer CNS control!
⚠️ Small, selected subgroup; exploratory findings. Indicated brain-directed therapy remains important.
📚 Saura Manich C et al. DESTINY-Breast09, LBA49, ESMO 2026.
@myESMO @OncoAlert @larvol #MVOnco #ESMO26 #BreastCancer
Sara Tolaney retweeted
🧠 HER2CLIMB-05 vs BRIDGET: When to Add Tucatinib in HER2+ Metastatic Breast Cancer?
🔹 HER2CLIMB-05 | BEFORE progression
HP maintenance + tucatinib
Phase III: PFS 24.9 vs 16.3 months (HR 0.64) ✅
🔹 BRIDGET | AFTER isolated brain progression
SRS → Continue HP + tucatinib
Phase II: Median brain PFS not reached vs historical 5-month benchmark; 18-month brain PFS 59%.
⚠️ Randomized benefit in HER2CLIMB-05; promising single-arm evidence in BRIDGET.
📚 Diéras et al., JCO; Sammons et al., ESMO Open, 2026.
@myESMO @OncoAlert @larvol #MVOnco #HER2 #BreastCancer
Sara Tolaney retweeted
Could ADCs replace chemotherapy as the backbone of breast cancer treatment?
At #ESMO26, Prof. Sara Tolaney @stolaney1 explores biomarker-guided treatment, endocrine resistance, and personalized treatment de-escalation.
Watch the full interview.
#BreastCancer #ADCs #Oncology
Sara Tolaney retweeted
@stolaney1 presenting the choice of 1L HER2+ MBC at the @Medscape Global Oncology session #ESMO2026 @myESMO @OncoAlert
Sara Tolaney retweeted
Great news👇
🚨Breaking🚨
Enhertu® Approved in the EU as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer
businesswire.com/news/home/2…
Learn more 👉 clin.larvol.com/trial-detail…
#LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #BreastCancer #BCSM | @stolaney1 | @ErikaHamilton9 | @PTarantinoMD | @curijoey | @dr_yakupergun | @hoperugo
Sara Tolaney retweeted
My #esmo26 breast summary: atirmo great data await phase 3; datodxd active in cns; pembro active in pdl1 >10 er+; Chinese “me too” need h2h; same payload no benefit; add tucatinib to delay cns progression; adj cdk os benefit (attn to stats) but giredestrant better tolerability.
Sara Tolaney retweeted
#BreastCancer research at #ESMO26 presented by Paolo Tarantino, MD (@PTarantinoMD) : ADC resistance appears to be driven by complex molecular adaptations beyond target modulation. Learn more in this video.
CC: @DFCI_BreastOnc
Sara Tolaney retweeted
The Gilead Young Investigator Research Grant Program (RSP) supports innovative research from emerging investigators around the world to incorporate new perspectives in our pursuits of scientific understanding and progress. Learn more: ow.ly/Pbog50ZXl84
Sara Tolaney retweeted
New findings from the FOURLIGHT-1 trial presented at #ESMO26 suggest atirmociclib plus Faslodex may help people with HR+, HER2-negative metastatic breast cancer live longer without the cancer growing.
🔗 Read more: bit.ly/4ewhPCh
#BreastCancer #BreastCancerResearch #ESMO26 #InsightsbyESMO #ClinicalTrials #Metavivor
Sara Tolaney retweeted
Joyce Liu, MD, MPH, providing her expertise in #EndometrialCancer during today's Presidential Symposium at #ESMO26. She'll be discussing: phase 3 results of a study looking at sacituzumab tirumotecan in previously treated advanced or recurrent endometrial cancer
Sara Tolaney retweeted
Joyce Liu, MD, MPH, takes the stage at the Presidential Symposium III as a discussant on results from the phase 3 TroFuse-005/ENGOT-en23/GOG-3095 study, evaluating sacituzumab tirumotecan in patients with previously treated advanced or recurrent endometrial cancer. #ESMO26
